Multicentric and multifocal versus unifocal breast cancer: Differences in the expression of E-cadherin suggest differences in tumor biology

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Weissenbacher, Tobias ^a,c   Hirte, Eva ^a   Kuhn, Christina ^a   Janni, Wolfgang ^b   Mayr, Doris ^c   Karsten, Uwe ^d   Rack, Brigitte ^a   Friese, Klaus ^a   Jeschke, Udo ^a   Heublein, Sabine ^a   Dian, Darius ^a   Ditsch, Nina ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d GLYCOTOPE GMBH   (Germany)

Author keywords

catenin; Breast cancer; E cadherin; MUC 1; Multicentric; Multifocal; Tumor biology

Indexed keywords

BETA CATENIN; MUCIN 1; UVOMORULIN; CADHERIN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTRIC MULTIFOCAL BREAST CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR VOLUME; UNIFOCAL BREAST CANCER; BIOSYNTHESIS; BREAST TUMOR; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

BREAST NEOPLASMS; CADHERINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84880940822     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-361     Document Type: Article

References (42)

1. Benson JR, Weaver DL, Mittra I, Hayashi M. The TNM staging system and breast cancer. Lancet Oncol 2003, 4(1):56-60. 10.1016/S1470-2045(03)00961-6, 12517540.
2. Escobar PF, Patrick RJ, Rybicki LA, Weng DE, Crowe JP. The 2003 revised TNM staging system for breast cancer: results of stage re-classification on survival and future comparisons among stage groups. Ann Surg Oncol 2007, 14(1):143-147.
3. Veronesi U, Viale G, Rotmensz N, Goldhirsch A. Rethinking TNM: breast cancer TNM classification for treatment decision-making and research. Breast 2006, 15(1):3-8.
4. Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev 2001, 27(3):137-142. 10.1053/ctrv.2000.0207, 11417963.
5. Dabakuyo TS, Bonnetain F, Roignot P, Poillot ML, Chaplain G, Altwegg T, Hedelin G, Arveux P. Population-based study of breast cancer survival in Cote d'Or (France): prognostic factors and relative survival. Ann Oncol 2008, 19(2):276-283. 10.1093/annonc/mdm491, 17962200.
6. Younes M, Lane M, Miller CC, Laucirica R. Stratified multivariate analysis of prognostic markers in breast cancer: a preliminary report. Anticancer Res 1997, 17(2B):1383-1390.
7. Weissenbacher TM, Zschage M, Janni W, Jeschke U, Dimpfl T, Mayr D, Rack B, Schindlbeck C, Friese K, Dian D. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?. Breast Cancer Res Treat 2010, 122(1):27-34. 10.1007/s10549-010-0917-9, 20454925.
8. Duraker N, Caynak ZC. Prognostic value of the 2002 TNM classification for breast carcinoma with regard to the number of metastatic axillary lymph nodes. Cancer 2005, 104(4):700-707. 10.1002/cncr.21199, 16003773.
9. Garcia Vilanova A, Sancho Merle MF, Vazquez Albaladejo C, Fuster Diana E, Cano Peral J. [Prognosis of stage II and III breast cancer in women and critique of various aspects of the TNM system]. Rev Esp Oncol 1980, 27(2):265-273.
10. Berx G, Nollet F, Van Roy F. Dysregulation of the E-cadherin/catenin complex by irreversible mutations in human carcinomas. Cell Adhes Commun 1998, 6(2-3):171-184.
11. Canavese G, Bernardi A, Candelaresi G, Lovadina P, Amerio S, Rossetti V, Rabagliati C, Berardengo E. Expression of the E-cadherin-catenins complex in sentinel node is related to tumor morphology but not to spread to nonsentinel nodes. Pathol Res Pract 2007, 203(7):517-523. 10.1016/j.prp.2007.03.003, 17576040.
12. Kuroda H, Tamaru J, Takeuchi I, Ohnisi K, Sakamoto G, Adachi A, Kaneko K, Itoyama S. Expression of E-cadherin, alpha-catenin, and beta-catenin in tubulolobular carcinoma of the breast. Virchows Arch 2006, 448(4):500-505. 10.1007/s00428-005-0096-y, 16538444.
13. Niu LG, He JJ, Wang K, Zhang W, Zhou C. Abnormal expression of beta-catenin and E-cadherin in Her2-positive breast cancer and its implications. Nan Fang Yi Ke Da Xue Xue Bao 2009, 29(11):2237-2240.
14. Baranwal S, Alahari SK. Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem Biophys Res Commun 2009, 384(1):6-11. 10.1016/j.bbrc.2009.04.051, 2700729, 19379710.
15. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009, 28(1-2):151-166.
16. Zheng G, Lyons JG, Tan TK, Wang Y, Hsu TT, Min D, Succar L, Rangan GK, Hu M, Henderson BR, et al. Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-beta1 in renal tubular epithelial cells. Am J Pathol 2009, 175(2):580-591. 10.2353/ajpath.2009.080983, 2716958, 19590041.
17. Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, Haga S, Kiyozuka Y, Schol D, Meulenbroek MF, et al. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996. Tumour Biol 1998, 19(Suppl 1):1-20.
18. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009, 9(12):874-885. 10.1038/nrc2761, 2951677, 19935676.
19. Danielczyk A, Stahn R, Faulstich D, Loffler A, Marten A, Karsten U, Goletz S. PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother 2006, 55(11):1337-1347. 10.1007/s00262-006-0135-9, 16485130.
20. Dian D, Janni W, Kuhn C, Mayr D, Karsten U, Mylonas I, Friese K, Jeschke U. Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies. Onkologie 2009, 32(5):238-244. 10.1159/000209280, 19420969.
21. Prasad CP, Rath G, Mathur S, Bhatnagar D, Parshad R, Ralhan R. Expression analysis of E-cadherin, slug and GSK3beta in invasive ductal carcinoma of breast. BMC Cancer 2009, 9:325. 10.1186/1471-2407-9-325, 2753637, 19751508.
22. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells?. Clin Cancer Res 2010, 16(12):3153-3162. 10.1158/1078-0432.CCR-09-2943, 20530697.
23. Sobin LH, Hermanek P, Hutter RV. TNM classification of malignant tumors. a comparison between the new (1987) and the old editions. Cancer 1988, 61(11):2310-2314. 10.1002/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X, 3284634.
24. Karsten U, Von Mensdorff-Pouilly S, Goletz S. What makes MUC1 a tumor antigen?. Tumour Biol 2005, 26(4):217-220. 10.1159/000086956, 16006776.
25. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19(5):403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
26. Vlastos G, Rubio IT, Mirza NQ, Newman LA, Aurora R, Alderfer J, Buzdar AU, Singletary SE. Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer. Ann Surg Oncol 2000, 7(8):581-587.
27. Tot T. Early and more advanced unifocal and multifocal breast carcinomas and their molecular phenotypes. Clin Breast Cancer 2011, 11(4):258-263. 10.1016/j.clbc.2011.02.004, 21729662.
28. Tot T, Pekar G. Multifocality in " basal-like" breast carcinomas and its influence on lymph node status. Ann Surg Oncol 2011, 18(6):1671-1677. 10.1245/s10434-010-1480-7, 21161724.
29. Tot T, Pekar G, Hofmeyer S, Gere M, Tarjan M, Hellberg D, Lindquist D. Molecular phenotypes of unifocal, multifocal, and diffuse invasive breast carcinomas. Patholog Res Int 2010, 2011:480960. 2995914, 21151538.
30. Boyages J, Jayasinghe UW, Coombs N. Multifocal breast cancer and survival: each focus does matter particularly for larger tumours. Eur J Cancer 2010, 46(11):1990-1996. 10.1016/j.ejca.2010.03.003, 20385484.
31. Pekar G, Hofmeyer S, Tabar L, Tarjan M, Chen TH, Yen AM, Chiu SY, Hellberg D, Gere M, Tot T. Multifocal breast cancer documented in large-format histology sections: long-term follow-up results by molecular phenotypes. Cancer 2013, 119(6):1132-1139. 10.1002/cncr.27877, 23279980.
32. Bassarova AV, Torlakovic E, Sedloev T, Hristova SL, Trifonov DV, Nesland JM. Simultaneous bilateral breast carcinoma: histopathological characteristics and CD44/catenin-cadherin profile. Histol Histopathol 2005, 20(3):791-799.
33. Mohinta S, Wu H, Chaurasia P, Watabe K. Wnt pathway and breast cancer. Front Biosci 2007, 12:4020-4033. 10.2741/2368, 17485355.
34. Lopez-Knowles E, Zardawi SJ, McNeil CM, Millar EK, Crea P, Musgrove EA, Sutherland RL, O'Toole SA. Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev 2010, 19(1):301-309. 10.1158/1055-9965.EPI-09-0741, 20056651.
35. Klopp AH, Lacerda L, Gupta A, Debeb BG, Solley T, Li L, Spaeth E, Xu W, Zhang X, Lewis MT, et al. Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One 2010, 5(8):e12180. 10.1371/journal.pone.0012180, 2922340, 20808935.
36. Debruyne P, Vermeulen S, Mareel M. The role of the E-cadherin/catenin complex in gastrointestinal cancer. Acta Gastroenterol Belg 1999, 62(4):393-402.
37. Bukholm IR, Nesland JM, Bukholm G. Expression of adhesion proteins E-cadherin, alpha-catenin, beta-catenin and gamma-catenin is different in T1 and T2 breast tumours. Pathology 2006, 38(5):403-407. 10.1080/00313020600922520, 17008277.
38. Yuan Z, Wong S, Borrelli A, Chung MA. Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochem Biophys Res Commun 2007, 362(3):740-746. 10.1016/j.bbrc.2007.08.074, 17764657.
39. Khodarev N, Ahmad R, Rajabi H, Pitroda S, Kufe T, McClary C, Joshi MD, MacDermed D, Weichselbaum R, Kufe D. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene 2010, 29(6):920-929. 10.1038/onc.2009.391, 2820589, 19915608.
40. De Oliveira JT, Pinho SS, De Matos AJ, Hespanhol V, Reis CA, Gartner F. MUC1 expression in canine malignant mammary tumours and relationship to clinicopathological features. Vet J 2009, 182(3):491-493. 10.1016/j.tvjl.2008.09.007, 18948041.
41. van der Vegt B, De Roos MA, Peterse JL, Patriarca C, Hilkens J, De Bock GH, Wesseling J. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology 2007, 51(3):322-335. 10.1111/j.1365-2559.2007.02757.x, 17645748.
42. De Roos MA, van der Vegt B, Peterse JL, Patriarca C, De Vries J, De Bock GH, Wesseling J. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast. Histopathology 2007, 51(2):227-238. 10.1111/j.1365-2559.2007.02754.x, 17650217.